NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read More
German Gynecological Oncology Group (AGO) includes BluePrint® in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
Read More
Agendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Read MoreNewsroom
News, Stories & Breast Cancer Blog
Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with about 1 in 8 women being diagnosed in their lifetime.[1] It also accounts for nearly 30% of all new female cancer diagnoses each year, with Read More
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleArticle: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
“These data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.”
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the ArticleDr. Nathalie Johnson Calls for Medical Community to Move to Action for Equality in Genomic Testing for Black Women
Dr. Nathalie McDowell Johnson, M.D., FACS, surgical oncologist and immediate past president of the American Society of Breast Surgeons shares her opinion in STAT News article on why Black women with breast cancer experience higher death rates and how utilizing a more advanced genomic test can provide a more comprehensive understanding and accurate risk evaluation.
Read the ArticleHIT Consultant: Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care
Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, recently spoke with HIT Consultant about why the conventional genomic test commonly used for breast cancer treatment planning is failing Black women, and in part, contributing to their disproportionately high mortality rate. Dr. Johnson discusses why MammaPrint provides more consistent results for Black women than the other gene expression profiling test, enabling more personalized treatment and improved outcomes.
Read the ArticleFierce Healthcare: Biden’s ‘Cancer Moonshot’ is already being fueled by tech addressing breast cancer
Fierce Healthcare recently spoke with Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, about the need for more widespread use of advanced gene expression profiling tests that provide more consistent results for Black women with early-stage breast cancer. Dr. Johnson highlights how the standard of care today negatively impacts outcomes for Black women, and why it is essential for clinicians to switch to more sophisticated, unbiased tests, such as MammaPrint & BluePrint, to address key disparities in breast cancer care.
Read the Article
